Skip to main content

Verve Therapeutics, Inc.

VERVDelisted Jul 25, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001840574

Verve Therapeutics, Inc. was delisted on Jul 25, 2025; its insiders filed their last Form 4 on Jul 28, 2025; 176 institutions reported holding it in 13F filings for Q2 2025, worth $819.4M in total; no superinvestor held it.

Q2 2023 vs. Q1 2023

How the institutions holding Verve Therapeutics, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of VERV: Q1 2023 compared with Q2 2023
MeasureQ1 2023Q2 2023Change
Holders125121−4
Shares63.3M61.9M−1.39M (−2.2%)
Value$911.8M$1.16B+$248.5M (+27.3%)

New holders (15)

Institutions that held Verve Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to VERV in Q2 2023
InstitutionSharesValue% of portfolio
Marshall Wace, LLP51,235$960.7K0.00%
American Century Companies Inc18,150$340.3K0.00%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.15,608$292.6K0.00%
Stifel Financial Corp13,759$258.0K0.00%
XTX Topco Ltd11,297$211.8K0.04%
Arizona State Retirement System11,289$211.7K0.00%
Dynamic Technology Lab Private Ltd11,051$207.0K0.03%
ProShare Advisors LLC10,605$198.8K0.00%
Caption Management, LLC5,700$106.9K0.02%
Itau Unibanco Holding S.A.1,172$22.0K0.00%
Simplex Trading, LLC324$6.00K0.00%
Quadrant Capital Group LLC192$3.60K0.00%
IFP Advisors, Inc6$1920.00%
Sofos Investments, Inc.19$610.00%
Motco1$190.00%

Sold out (19)

Institutions that held Verve Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.